Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo: A Prospective, Randomized Study Using the Two-Step Hyperinsulinemic, Euglycemic Clamp

Margaret Sowell, Nitai Mukhopadhyay, Patrizia Cavazzoni, Christopher Carlson, Sunder Mudaliar, Sithiphol Chinnapongse, Amy Ray, Trent Davis, Alan Breier, Robert R. Henry, Jamie Dananberg

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

The primary objective of this study was to evaluate insulin sensitivity in healthy subjects treated with olanzapine or risperidone. Subjects were randomly assigned to single-blind therapy with olanzapine (10 mg/d), risperidone (4 mg/d), or placebo for approximately 3 wk. Insulin sensitivity was assessed pre- and posttreatment using a 2-step, hyperinsulinemic, euglycemic clamp. Glucose and insulin responses were also assessed by a mixed meal tolerance test. Of the 64 subjects randomized, 22, 14, and 19 in the olanzapine, risperidone, and placebo groups, respectively, completed the study procedures. There were no significant within-group changes in the glucose disposal rate or the insulin sensitivity index for the active therapy groups. Further, the results of the mixed meal tolerance test did not demonstrate clinically significant changes in integrated glucose metabolism during treatment with these medications. In summary, this study did not demonstrate significant changes in insulin sensitivity in healthy subjects after 3 wk of treatment with olanzapine or risperidone.

Original languageEnglish (US)
Pages (from-to)5875-5880
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume88
Issue number12
DOIs
StatePublished - Dec 2003

Fingerprint

olanzapine
Glucose Clamp Technique
Risperidone
Clamping devices
Insulin Resistance
Healthy Volunteers
Placebos
Prospective Studies
Insulin
Glucose
Meals
Group Psychotherapy
Therapeutics
Metabolism

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo : A Prospective, Randomized Study Using the Two-Step Hyperinsulinemic, Euglycemic Clamp. / Sowell, Margaret; Mukhopadhyay, Nitai; Cavazzoni, Patrizia; Carlson, Christopher; Mudaliar, Sunder; Chinnapongse, Sithiphol; Ray, Amy; Davis, Trent; Breier, Alan; Henry, Robert R.; Dananberg, Jamie.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 88, No. 12, 12.2003, p. 5875-5880.

Research output: Contribution to journalArticle

Sowell, Margaret ; Mukhopadhyay, Nitai ; Cavazzoni, Patrizia ; Carlson, Christopher ; Mudaliar, Sunder ; Chinnapongse, Sithiphol ; Ray, Amy ; Davis, Trent ; Breier, Alan ; Henry, Robert R. ; Dananberg, Jamie. / Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo : A Prospective, Randomized Study Using the Two-Step Hyperinsulinemic, Euglycemic Clamp. In: Journal of Clinical Endocrinology and Metabolism. 2003 ; Vol. 88, No. 12. pp. 5875-5880.
@article{e6a877e7af6a4bc8b552b75e1df2dc95,
title = "Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo: A Prospective, Randomized Study Using the Two-Step Hyperinsulinemic, Euglycemic Clamp",
abstract = "The primary objective of this study was to evaluate insulin sensitivity in healthy subjects treated with olanzapine or risperidone. Subjects were randomly assigned to single-blind therapy with olanzapine (10 mg/d), risperidone (4 mg/d), or placebo for approximately 3 wk. Insulin sensitivity was assessed pre- and posttreatment using a 2-step, hyperinsulinemic, euglycemic clamp. Glucose and insulin responses were also assessed by a mixed meal tolerance test. Of the 64 subjects randomized, 22, 14, and 19 in the olanzapine, risperidone, and placebo groups, respectively, completed the study procedures. There were no significant within-group changes in the glucose disposal rate or the insulin sensitivity index for the active therapy groups. Further, the results of the mixed meal tolerance test did not demonstrate clinically significant changes in integrated glucose metabolism during treatment with these medications. In summary, this study did not demonstrate significant changes in insulin sensitivity in healthy subjects after 3 wk of treatment with olanzapine or risperidone.",
author = "Margaret Sowell and Nitai Mukhopadhyay and Patrizia Cavazzoni and Christopher Carlson and Sunder Mudaliar and Sithiphol Chinnapongse and Amy Ray and Trent Davis and Alan Breier and Henry, {Robert R.} and Jamie Dananberg",
year = "2003",
month = "12",
doi = "10.1210/jc.2002-021884",
language = "English (US)",
volume = "88",
pages = "5875--5880",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo

T2 - A Prospective, Randomized Study Using the Two-Step Hyperinsulinemic, Euglycemic Clamp

AU - Sowell, Margaret

AU - Mukhopadhyay, Nitai

AU - Cavazzoni, Patrizia

AU - Carlson, Christopher

AU - Mudaliar, Sunder

AU - Chinnapongse, Sithiphol

AU - Ray, Amy

AU - Davis, Trent

AU - Breier, Alan

AU - Henry, Robert R.

AU - Dananberg, Jamie

PY - 2003/12

Y1 - 2003/12

N2 - The primary objective of this study was to evaluate insulin sensitivity in healthy subjects treated with olanzapine or risperidone. Subjects were randomly assigned to single-blind therapy with olanzapine (10 mg/d), risperidone (4 mg/d), or placebo for approximately 3 wk. Insulin sensitivity was assessed pre- and posttreatment using a 2-step, hyperinsulinemic, euglycemic clamp. Glucose and insulin responses were also assessed by a mixed meal tolerance test. Of the 64 subjects randomized, 22, 14, and 19 in the olanzapine, risperidone, and placebo groups, respectively, completed the study procedures. There were no significant within-group changes in the glucose disposal rate or the insulin sensitivity index for the active therapy groups. Further, the results of the mixed meal tolerance test did not demonstrate clinically significant changes in integrated glucose metabolism during treatment with these medications. In summary, this study did not demonstrate significant changes in insulin sensitivity in healthy subjects after 3 wk of treatment with olanzapine or risperidone.

AB - The primary objective of this study was to evaluate insulin sensitivity in healthy subjects treated with olanzapine or risperidone. Subjects were randomly assigned to single-blind therapy with olanzapine (10 mg/d), risperidone (4 mg/d), or placebo for approximately 3 wk. Insulin sensitivity was assessed pre- and posttreatment using a 2-step, hyperinsulinemic, euglycemic clamp. Glucose and insulin responses were also assessed by a mixed meal tolerance test. Of the 64 subjects randomized, 22, 14, and 19 in the olanzapine, risperidone, and placebo groups, respectively, completed the study procedures. There were no significant within-group changes in the glucose disposal rate or the insulin sensitivity index for the active therapy groups. Further, the results of the mixed meal tolerance test did not demonstrate clinically significant changes in integrated glucose metabolism during treatment with these medications. In summary, this study did not demonstrate significant changes in insulin sensitivity in healthy subjects after 3 wk of treatment with olanzapine or risperidone.

UR - http://www.scopus.com/inward/record.url?scp=9144219732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144219732&partnerID=8YFLogxK

U2 - 10.1210/jc.2002-021884

DO - 10.1210/jc.2002-021884

M3 - Article

C2 - 14671184

AN - SCOPUS:9144219732

VL - 88

SP - 5875

EP - 5880

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 12

ER -